Silence Therapeutics PLC Notice of AGM (8497X)
May 07 2021 - 2:00AM
UK Regulatory
TIDMSLN
RNS Number : 8497X
Silence Therapeutics PLC
07 May 2021
Notice of Annual General Meeting
7 May 2021
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN
("Silence" or "the Company"), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announced that this year's
Annual General Meeting ("AGM") of the Company will be held on 15
June 2021 at 72 Hammersmith Road, London W14 8TH at 12:00 p.m.
(noon) (BST).
The Notice of AGM has been posted to shareholders and is
available on the Investor's section of the Company's website at
www.silence-therapeutics.com.
Due to the restrictions on movement and gatherings imposed by
the UK Government in response to the COVID-19 pandemic,
shareholders, advisers and other guests will not be allowed to
attend the AGM in person and anyone seeking to attend the meeting
will be refused entry. As such, shareholders should note they are
not entitled to attend the AGM in person unless notified otherwise
via the Company's website at https://www.silence-therapeutics.com
and via RNS announcement.
Shareholders are strongly encouraged to therefore submit their
votes, in respect of all matters of business, via proxy as early as
possible. Shareholders should appoint the Chairman of the meeting
as their proxy. If a shareholder appoints someone else as their
proxy, that proxy will not be able to attend the AGM in person and
cast the shareholder's vote.
In light of the fact that we are holding a closed AGM due to
ongoing COVID-19 restrictions, we are pleased to be able to provide
a facility for shareholders to access the AGM remotely and follow
the business of the AGM by webcast, together with facilities for
shareholders to submit questions by email in advance or live during
the webcast. Shareholders should refer to the Notice of AGM for
details.
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR & Corporate Communications
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European PR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary mRNAi GOLD(TM) platform can be
used to create siRNAs that precisely target and silence
disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address iron
loading anemias. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Takeda, among others. For more information,
please visit https://www.silence-therapeutics.com/.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOASSIEFMEFSEDI
(END) Dow Jones Newswires
May 07, 2021 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024